RNS Number:6145N
Shore Capital Group PLC
16 July 2003



For Immediate Release
                                                             16 July 2003

             Disposal of Holding in XTL Biopharmaceuticals  ("XTL")


The investor group, of Shore Capital Stockbrokers Limited and its clients,
announces that it has sold 14.45m shares @ 12p per share in XTL representing
approximately 13% of the issued share capital of the Company and has retained an
interest of approximately 5% in the Company.  The shares have been purchased by
Israel Healthcare Ventures, which is a venture capital fund dedicated to
providing venture capital investment to Israeli life sciences companies.


XTL announced yesterday that its Board had agreed a plan to focus the company's
efforts on developing its most advanced products and to conserve its cash.  It
stated that it would be reducing its R&D headcount and cutting cash burn from
approximately $1.4m per month to approximately $900,000 per month.  As a result
it stated that it expected its cash resources to last at least until the first
quarter of 2006.  It also announced measures to "drive forward" licensing and
partner negotiations.


Howard Shore, Chairman of Shore Capital, said: "We are pleased to note the
adoption of this plan and the increased focus on delivering shareholder value.
We are also delighted that a group of Israel Healthcare Ventures skills and
expertise has become a major shareholder in XTL."


Enquiries:


Howard Shore              Shore Capital          020 7468 7911

Tim Jackaman              Weber Shandwick        020 7067 0700

Rochel Velasco            Weber Shandwick        020 7067 0713


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

HOLRFMBTMMTBBLJ